{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graves%27+Dysthyroid+Ophthalmopathy&page=2",
    "query": {
      "condition": "Graves' Dysthyroid Ophthalmopathy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graves%27+Dysthyroid+Ophthalmopathy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T06:11:03.081Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03298867",
      "title": "Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease",
        "Graves' Orbitopathy"
      ],
      "interventions": [
        {
          "name": "Teprotumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 83,
      "start_date": "2017-10-04",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 9,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03298867"
    },
    {
      "nct_id": "NCT06307626",
      "title": "A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo PH20 SC",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2024-03-28",
      "completion_date": "2026-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06307626"
    },
    {
      "nct_id": "NCT01927406",
      "title": "The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thyroid Eye Disease",
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Prostaglandin Analog",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-06",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2018-05-15",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01927406"
    },
    {
      "nct_id": "NCT01868997",
      "title": "Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Associated Ophthalmopathies",
        "Thyroid-Associated Ophthalmopathy"
      ],
      "interventions": [
        {
          "name": "teprotumumab",
          "type": "DRUG"
        },
        {
          "name": "normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 88,
      "start_date": "2013-07",
      "completion_date": "2017-02-22",
      "has_results": true,
      "last_update_posted_date": "2024-12-17",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868997"
    },
    {
      "nct_id": "NCT06625411",
      "title": "An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "VRDN-003",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viridian Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 132,
      "start_date": "2024-08-27",
      "completion_date": "2026-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 34,
      "location_summary": "Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 25 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06625411"
    },
    {
      "nct_id": "NCT06467435",
      "title": "Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Kamuvudine-9",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peter Timoney",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4,
      "start_date": "2024-11-06",
      "completion_date": "2026-02-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06467435"
    },
    {
      "nct_id": "NCT06112340",
      "title": "Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease",
        "Graves Orbitopathy",
        "Endocrine System Diseases",
        "Eye Diseases",
        "Thyroid Associated Ophthalmopathy",
        "Graves Ophthalmopathy",
        "Thyroid Diseases",
        "Orbital Diseases",
        "Proptosis",
        "IGF1R",
        "Exophthalmos",
        "Hashimoto"
      ],
      "interventions": [
        {
          "name": "linsitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sling Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2023-10-11",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Morgantown, West Virginia",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06112340"
    },
    {
      "nct_id": "NCT07155668",
      "title": "A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "VRDN-003",
          "type": "DRUG"
        },
        {
          "name": "Autoinjector",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Viridian Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 87,
      "start_date": "2025-07-01",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 13,
      "location_summary": "Inglewood, California • Cape Coral, Florida • Kissimmee, Florida + 7 more",
      "locations": [
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Cape Coral",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07155668"
    },
    {
      "nct_id": "NCT02845336",
      "title": "Celecoxib for Thyroid Eye Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "artificial tears",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2017-03-05",
      "completion_date": "2019-06-30",
      "has_results": true,
      "last_update_posted_date": "2020-07-31",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02845336"
    },
    {
      "nct_id": "NCT06812325",
      "title": "A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease (TED)"
      ],
      "interventions": [
        {
          "name": "VRDN-003",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viridian Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 320,
      "start_date": "2025-02-03",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-10T06:11:03.081Z",
      "location_count": 32,
      "location_summary": "Tuscon, Arizona • Inglewood, California • Newport Beach, California + 25 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Pismo Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06812325"
    }
  ]
}